

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*,¹

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**NOTICE OF CANCELLATION OF AUCTION(S), DESIGNATION OF WINNING BID
FOR THE LONAFARNIB SALE TRANSACTION, AND TRANSITION TO PRIVATE
SALE PROCESS FOR LONAFARNIB/LAMBDA SALE TRANSACTIONS**

PLEASE TAKE NOTICE that, on April 5, 2024 the Court entered the *Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentyln Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), if Any; (D) Establishing Bid Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; And (III) Granting Related Relief* [Docket No. 94] (the “Bid Procedures Order”),² which, among other things, establishes key dates and deadlines related to the Auction for, and the Sale of, the Assets.

PLEASE TAKE FURTHER NOTICE that, on April 8, 2024, and June 3, 2024, the Debtors served the *Notice of Sale, Bid Procedures, Auction, and Sale Hearing* on all known parties in interest. See Docket Nos. 128, 320.

PLEASE TAKE FURTHER NOTICE that, on April 15, 2024, the Debtors filed the *Notice of Filing of Revised Bidding Procedures* [Docket No. 119], which included the revised bidding procedures (the “Bid Procedures”) attached as Exhibit A.

PLEASE TAKE FURTHER NOTICE that, on June 12, 2024, the Debtors filed and served the *Revised Notice of Sale, Bid Procedures, Auction, and Sale Hearing* [Docket No. 331] on all known parties in interest. See Docket Nos. 374, 431.

¹ The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Avenue, Dallas, Texas 75201.

² Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Bid Procedures Motion, the Bid Procedures, and the Bid Procedures Order, as applicable.

PLEASE TAKE FURTHER NOTICE that, on July 13, 2024, Debtors filed the *Further Revised Notice of Bid Deadlines* [Docket No. 422], which included revised dates and deadlines related to the Bid Deadline for the Lonafarnib sale transaction (the “Lonafarnib Sale Transaction”) and the Lambda sale transaction (the “Lambda Sale Transaction”).

PLEASE TAKE FURTHER NOTICE that, as of July 19, 2024 at 4:00 p.m. (prevailing Central Time), which was the Bid Deadline for the Lonafarnib Sale Transaction, the Debtors only received one Qualified Bid for the Lonafarnib Sale Transaction from Eiger InnoTherapeutics, Inc. (“Inno”).

PLEASE TAKE FURTHER NOTICE that, in accordance with the Bid Procedures the Debtors have **cancelled** the Auction and hereby designate Inno as the highest and best bid with a Base Price in the amount of \$5,200,000 (the “Winning Lonafarnib Bid”).

PLEASE TAKE FURTHER NOTICE that Inno seeks to purchase the Lonafarnib Assets free and clear of liens, claims, encumbrances, and other interests on the terms set forth in the Asset Purchase Agreement by and between Inno and Eiger BioPharmaceuticals, Inc. (the “Lonafarnib APA”).

PLEASE TAKE FURTHER NOTICE that, the Debtors have designated Inno as the highest and best bid with a Base Price in the amount of \$1,000,000 (the “Winning Lambda Bid”).

PLEASE TAKE FURTHER NOTICE that the Debtors have **cancelled** the Auction for the Lambda Sale Transaction and, on August 1, 2024, executed an asset purchase agreement by and between Inno and Eiger BioPharmaceuticals, Inc. for the Lambda Sale Transaction (the “Lambda APA”).

PLEASE TAKE FURTHER NOTICE that, under the Lonafarnib APA and the Lambda APA, Inno has agreed to pay certain cure costs in an amount up to \$2,650,000 in the aggregate if certain conditions are met.

PLEASE TAKE FURTHER NOTICE that Inno seeks to purchase the Lambda Assets free and clear of liens, claims, encumbrances, and other interests on the terms set forth in the Lambda APA.

PLEASE TAKE FURTHER NOTICE that the Debtors will file a motion seeking approval of the Lonafarnib Sale Transaction and the Lambda Sale Transaction (the “Lonafarnib/Lambda Sale Motion”). The Debtors will seek approval of the Lonafarnib Sale Transaction, the Lambda Sale Transaction, and the Lonafarnib/Lambda Sale Motion on an expedited basis at a to-be-scheduled hybrid hearing.

PLEASE TAKE FURTHER NOTICE that attached as **Exhibit A** and **Exhibit B** is a list of the Assigned Contracts and applicable Cure Amounts for each respective Assigned Contract that Inno has indicated will be cured by, and assigned to, Inno pursuant to the Lonafarnib Sale Transaction and the Lambda Sale Transaction, respectively. As more fully described in the Lonafarnib APA and the Lambda APA, Inno retains the right to modify the list of Assigned Contracts prior to Closing. The Debtors hereby certify that the Debtors will provide, in

coordination with the proposed assignee, Inno's Adequate Assurance Information to each affected Counterparty on a confidential basis.

PLEASE TAKE FURTHER NOTICE that copies of foregoing pleadings, including of the Bid Procedures, are available by: (i) visiting the website of the Debtors' claims, noticing, and solicitation agent, Kurtzman Carson Consultants LLC dba Verita Global ("Verita") at <https://www.veritaglobal.net/Eiger>, (ii) (888)733-1544 (Toll-Free) or (310 751-2638 (International), and/or (iii) emailing <https://www.veritaglobal.net/Eiger/inquiry> or (iv) for a fee via PACER at <https://ecf.txnb.gov/>.

PLEASE TAKE FURTHER NOTICE that you may obtain additional information concerning these Chapter 11 Cases on the Case Website.

[Remainder of page intentionally left blank]

Dated: August 2 2024
Dallas, Texas

SIDLEY AUSTIN LLP

/s/ Thomas R. Califano

Thomas R. Califano (TX Bar No. 24122825)
William E. Curtin (admitted *pro hac vice*)
Anne G. Wallice (admitted *pro hac vice*)
787 Seventh Avenue
New York, NY 10019
Telephone: (212) 839-5300
Facsimile: (212) 839-5599
Email: tom.califano@sidley.com
wcurtin@sidley.com
anne.wallice@sidley.com

and

Charles M. Persons (TX Bar No. 24060413)
2021 McKinney Avenue, Suite 2000
Dallas, Texas 75201
Telephone: (214) 981-3300
Facsimile: (214) 981-3400
Email: cpersons@sidley.com

Attorneys for the Debtors and Debtors in Possession

Certificate of Service

I certify that on August 2, 2024, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Northern District of Texas.

/s/ Thomas R. Califano
Thomas R. Califano

Exhibit A

Lonafarnib Assigned Contracts and Cure Amounts

Asset	Counterparty	Description of Contract	Cure Amounts
Lonafarnib	LONZA BEND, INC. (f.k.a. Bend Research, Inc.)	Change Order 7 to Statement of Work	\$0.00
Lonafarnib	LONZA BEND, INC. (f.k.a. Bend Research, Inc.)	Amendment No. 2 to the Master Services and Clinical Manufacture Agreement	
Lonafarnib	LONZA BEND, INC. (f.k.a. Bend Research, Inc.)	Master Services and Clinical Manufacture Agreement	
Lonafarnib	BIORASI, LLC	Master Services Agreement, dated June 23, 2020	[\$●] ¹
Lonafarnib	BIORASI, LLC	Statement of Work #157-1, dated July 10, 2020, as governed by Master Services Agreement, dated June 23, 2020	
Lonafarnib	BIORASI, LLC	Change Order 1 to Statement of Work #157-1	
Lonafarnib	BIORASI, LLC	Change Order 2 to Statement of Work #157-1	
Lonafarnib	BIORASI, LLC	Change Order 3 to Statement of Work #157-1	
Lonafarnib	BIORASI, LLC	Change Order 4 to Statement of Work #157-1, dated October 29, 2021	
Lonafarnib	CHARLES RIVER LABORATORIES	1st Amendment to Statement of Work (SFDC OPP 273814) [20230131]	\$0.00
Lonafarnib	CHARLES RIVER LABORATORIES	2nd Amendment to Statement of Work (SFDC OPP-273814)	
Lonafarnib	CHARLES RIVER LABORATORIES MONTREAL ULC	Master Services Agreement	\$0.00
Lonafarnib	Corden Pharma Colorado	Change Order #6 to Statement of Work, dated May 19, 2021	\$0.00
Lonafarnib	Corden Pharma Colorado	Change Order #6 to Statement of Work, dated November 5, 2019	
Lonafarnib	Corden Pharma Colorado	Statement of Work 6	
Lonafarnib	Corden Pharma Colorado; Corden Pharma International GmbH	Change Order 1 to the Statement of Work 6	\$0.00

¹ The Biorasi, LLC (“Biorasi”) contract cure amounts are subject to resolution among the Debtors, Biorasi, and the Purchaser.

Lonafarnib	Cyprotex US, LLC	Proposal for Analysis of Active Metabolites of Lonafarnib (LNF): MH17 and HM21	\$0.00
Lonafarnib	Fiona McPhee, DPhil	Services Agreement	\$2,612.50
Lonafarnib	Fisher Clinical Services GmbH	Quote 214873 Order 8 Version 3 20220225	\$0.00
Lonafarnib	Fisher Clinical Services Inc.	Quote PSG-A-1051277.v3 20220225	\$5,673.53
Lonafarnib	Fisher Clinical Services Inc.	Quote-PSG-A-1072091.v2 20230302	
Lonafarnib	Fisher Clinical Services U.K. Limited	Quote PSG-A-1007765.v1 20190514	\$0.00
Lonafarnib	INTRINSIK CORP	Statement of Work #8, dated July 9, 2022, as governed by Master Services Agreement, dated March 6, 2020	\$55.00
Lonafarnib	LONZA BEND, INC.	Amendment No. 1 to the Commercial Supply Agreement	\$21,000.00
Lonafarnib	LONZA BEND, INC.	Amendment No. 2 to the Commercial Supply Agreement	
Lonafarnib	LONZA BEND, INC.	Change Order 8 to Statement of Work	
Lonafarnib	LONZA BEND, INC.	Master Services and Clinical Manufacture Agreement, dated 15 December, 2022	
Lonafarnib	LONZA BEND, INC.	Statement of Work, dated 10 April 2023	
Lonafarnib	Lonza Bend; Patheon Canada	Total Transportation Management (“TTM”) Freight Quote	\$0.00
Lonafarnib	Lonza Pharma & BioTech	Change Order #7 to E141-8598	\$0.00
Lonafarnib	Lonza Pharma & BioTech	Change Order No.1 to Statement of Work	
Lonafarnib	Lonza Pharma & BioTech	Stability Proposal	
Lonafarnib	Lonza Pharma & BioTech	Validation Proposal, dated 6 April 2020	
Lonafarnib	Patheon, Inc.	Solely the extent related to the 25mg strength, Change of Scope COS-55-R0 to Proposal No. P-TRP-114750-R2	

Lonafarnib	Patheon, Inc.	Project Proposal, dated July 27, 2019	\$[●] ²
Lonafarnib	Patheon, Inc.	Project Proposal, dated July 27, 2019	
Lonafarnib	Patheon, Inc.	Project Proposal # C-TRC-270507-R4, dated September 27, 2021	
Lonafarnib	Patheon, Inc.	Change of Scope # C-TRC-270507-R4-COS-01-R0	
Lonafarnib	Patheon, Inc.	Master Manufacturing Services Agreement, dated January 9, 2020	
Lonafarnib	Patheon UK Limited; Fisher Clinical Services	Change of Scope: Proposal COS 12 to C-TRC-121992-R4_20230429	\$0.00
Lonafarnib	Patheon, Part of Thermo Fischer Scientific; Element Toronto	Element Quote Element_Quote 20-012162900 Rev 1_20200420	\$0.00
Lonafarnib	Patheon, Part of Thermofisher	Total Transportation Management (“TTM”) Freight Quote 453021_20201202	\$0.00
Lonafarnib	PharmaDirections, Inc	WKO-EIG-879 Ad hoc Consulting	\$2,767.50
Lonafarnib	Q SQUARED SOLUTIONS HOLDINGS, LLC	Work Order, dated October 20, 2023, under that certain Master Laboratory Services Agreement, dated May 3, 2019	\$0.00
Lonafarnib	RRD INTERNATIONAL, LLC	Project Agreement 1 to the Product Development Agreement, dated July 1, 2018, as governed by Product Development Agreement, dated July 1, 2018	\$45,368.75
Lonafarnib	RRD INTERNATIONAL, LLC	Amended and Restated Work Order No. 11 to the Master Services Agreement	
Lonafarnib	RRD INTERNATIONAL, LLC	Interim CO 1 to PA 1 Amendment 3	
Lonafarnib	RRD INTERNATIONAL, LLC	Product Development Agreement, dated July 1, 2018	

² The Patheon, Inc. (“Patheon”) contract cure amounts are subject to resolution among the Debtors, Patheon, and the Purchaser.

Lonafarnib	Trialog Clinical Trials Ltd	Study Protocol No.: EIG-LNF-011, dated July 18, 2019	\$0.00
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2019120, dated August 14, 2019	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #201989, dated December 3, 2019	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2020017, dated January 27, 2020	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2020082, dated March 30, 2020	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2020191, dated July 28, 2020	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2020201, dated August 9, 2020	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2020348, dated December 31, 2020	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2021-028, dated January 25, 2021	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #2021-210, dated June 8, 2021	
Lonafarnib	Trialog Clinical Trials Ltd	Study Protocol No.: SCRC20042, dated June 7, 2021	
Lonafarnib	Trialog Clinical Trials Ltd	Price Quote #20221259, dated July 20, 2022	
Lonafarnib	LONZA BEND, INC. (f.k.a. Bend Research, Inc.)	Commercial Manufacturing Services and Supply Agreement, dated October 9, 2019*	\$0.00
Lonafarnib	LONZA BEND, INC. (f.k.a. Bend Research, Inc.)	Commercial Quality Agreement, dated October 17, 2019, as amended by Amendment No. 1 to Quality Agreement, dated February 15, 2023	
Lonafarnib	CordenPharma	Master Services Agreement, dated March 22, 2016	\$0.00
Lonafarnib	CordenPharma	Commercial Quality Agreement, dated February 19, 2020	

Lonafarnib	Fisher Clinical Services, Inc.	Master Services Agreement, Inc. dated May 6, 2016	\$0.00
Lonafarnib	Fisher Clinical Services, Inc.	First Amendment and Restated Quality Agreement, dated February 23, 2021	\$0.00
Lonafarnib	INSERM U1110, Université de Strasbourg, France	Project Proposal 1	\$0.00
Lonafarnib	U1111, Centre International de Recherche en Infectiologie, Lyon, France, team HepVir	Project Proposal V-2023-03-16, dated March 16, 2023	\$0.00
N/A	Eiger Group International, Inc.	Asset Purchase Agreement, dated December 8, 2010	\$0.00
Lonafarnib	EZUS LYON (Subsidiary of the Université Claude Bernard Lyon 1), Subsidiary of the Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon, and Inserm Transfert SA	Research Agreement, dated February 15, 2024.	\$173,200.51
Lonafarnib	SATT Conectus Alsace, University of Strasbourg, French National Institute of Health and Medical Research, and Institute for Viral and Liver Diseases	Sponsored Research Agreement, dated January 12, 2024.	\$0.00
Lonafarnib	IQVIA Biotech LLC	Change Proposal No. 15	\$[●]³
Lonafarnib	IQVIA Clinical AB	Letter of Delegation re: Protocol Number EIG-LNF-011	
Lonafarnib	IQVIA RDS INC.	Change Order 3 to MSA	
Lonafarnib	IQVIA RDS INC.	General Services Agreement:	

³ The IQVIA Biotech LLC, IQVIA Clinical AB, and IQVIA RDS INC., (collectively, “IQVIA”) contract cure amounts are subject to resolution among the Debtors, IQVIA, and the Purchaser.

Lonafarnib	Novella Clinical LLC	Change Proposal 2	\$0.00
Lonafarnib	Novella Clinical LLC	Change Proposal 3	
Lonafarnib	Novella Clinical LLC	Change Proposal 4	
Lonafarnib	Novella Clinical LLC	Change Proposal 6	
Lonafarnib	Novella Clinical LLC	Change Proposal 7	

Exhibit B

Lambda Assigned Contracts and Cure Amounts

Assigned Contracts and Cure Amounts

Asset	Counterparty	Description of Contract	Cure Amounts
Lambda	BECTON, DICKINSON AND COMPANY	Quote re: Pharmaceutical Products	\$0.00
Lambda	BIORASI, LLC	Statement of Work #157-2, dated April 16, 2021, as governed by Master Services Agreement, dated June 23, 2020	\$[●] ¹
Lambda	BIORASI, LLC	Change Order 1 to Statement of Work #157-2, dated December 29, 2021	
Lambda	BIORASI, LLC	Change Order 2 to Statement of Work #157-2, dated December 20, 2021	
Lambda	BIORASI, LLC	Statement of Work #157-3, dated January 21, 2021, as governed by Master Services Agreement, dated June 23, 2020	
Lambda	BRISTOL-MYERS SQUIBB COMPANY	Assignment and Assumption Agreement	\$0.00
Lambda	BRISTOL-MYERS SQUIBB COMPANY	Common Stock Purchase Agreement	
Lambda	BRISTOL-MYERS SQUIBB COMPANY	License Agreement, dated April 20, 2016	
Lambda	CHARLES RIVER LABORATORIES, INC.	Statement of Work, dated December 31, 2020	\$0.00
Lambda	CHARLES RIVER LABORATORIES, INC.	Statement of Work, dated December 31, 2021	
Lambda	CHARLES RIVER LABORATORIES, INC.	Statement of Work re: Evaluation of the Stability of E.coli Working Cell Bank	
Lambda	CHARLES RIVER LABORATORIES, INC.	Statement of Work re: Preparation and Characterization of an E. coli Master Cell Bank	
Lambda	CHARLES RIVER LABORATORIES, INC.	Statement of Work re: Storage of Materials Under Controlled Conditions and Access	

¹ The Biorasi, LLC (“Biorasi”) contract cure amounts are subject to resolution among the Debtors, Biorasi, and the Purchaser.

Asset	Counterparty	Description of Contract	Cure Amounts
Lambda	Eurofins Biopharma Product Testing	Quotation #HEY2PH220237-01 re: Establishment of a Method for Free PEG by HPLC-CAD, dated May 26, 2022	\$0.00
Lambda	Eurofins Biopharma Product Testing	Quotation #HEY2PH220237-02 re: Establishment of a Method for Free PEG by HPLC-CAD, dated November 9, 2022	
Lambda	Eurofins BioPharma Product Testing	Quotation #VFK8PH210375-01 re: FBS Qualification for for Lambda-1 (Python), dated September 14, 2021	
Lambda	Eurofins Lancaster Laboratories (Lancaster PA)	Quotation #W9MYPH200689-02, dated December 4, 2020	\$0.00
Lambda	Eurofins Lancaster Laboratories (Lancaster PA)	Quotation #W9MYPH200689-05, dated April 18, 2022	
Lambda	Eurofins Lancaster Laboratories (Lancaster PA)	Quotation #NQ-0143063, dated December 5, 2016	
Lambda	Eurofins Lancaster Laboratories (Lancaster PA)	Quotation #NQ-0148470, dated March 15, 2017	
Lambda	FISHER BIOSERVICES, INC.	Statement of Work	\$[●] ²
Lambda	Fisher Clinical Services Inc.	CO 1 to PSG-A-1073971 (PSG-A-1076893) 20230524	\$29,097.55
Lambda	Fisher Clinical Services Inc.	Quote 20160517	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A- 1043137.v1 20210812	
Lambda	Fisher Clinical Services Inc.	Quote 20160927	
Lambda	Fisher Clinical Services Inc.	Quote FCS 55799 20170221	
Lambda	Fisher Clinical Services Inc.	Quote FCS 55799 Change Order 1 20161116	

² The Fisher BioServices, Inc. (“Fisher”) contract cure amount is subject to resolution among the Debtors, Fisher, and the Purchaser.

Asset	Counterparty	Description of Contract	Cure Amounts
Lambda	Fisher Clinical Services Inc.	Quote FCS 55799 Order 7 20170629	
Lambda	Fisher Clinical Services Inc.	Quote FCS 55799 Order 8 20180918	
Lambda	Fisher Clinical Services Inc.	Quote FCS 58040 20161206	
Lambda	Fisher Clinical Services Inc.	Quote FCS 62278 20180309	
Lambda	Fisher Clinical Services Inc.	Quote FCS 68128 Order 1 Version 1 20190720	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1007253 V2 20190508	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1009306.V1 20190619	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1037571.v1 20210414	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1037572.v1_20210420	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1037587.v1 20210420	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1038183.v1 20210422	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1040820.V3 20210713	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1041275.v4 20210819	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1044658.v1 20210902	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1045926.v1 20210927	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1053812.v2 20220323	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1056697.v1 20221205	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1060127.v1 20221205	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1072645 v1 20230420	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1073971 20230429	
Lambda	Fisher Clinical Services Inc.	Quote PSG-A-1086699.v1 20231128	

Asset	Counterparty	Description of Contract	Cure Amounts
Lambda	Fisher Clinical Services Inc.	Quote re: Protocol No. EIG-LMD-001	
Lambda	Fisher Clinical Services Inc.	Quote-PSG-A-1037570.v2 20210423	
Lambda	Fisher Clinical Services Inc.	Quote-PSG-A-1045938.v1 20210927	
Lambda	Fisher Clinical Services Inc.	Quote-PSG-A-1069905.v1 20230204	
Lambda	Fujifilm Diosynth	Stability Studies Termination, Accountability and Reconciliation Memo	\$[●] ³
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	2020 (“SOW9”) and the Master Bioprocessing Services Agreement	
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	Bioprocessing Services Agreement, dated October 15, 2019	
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	Bioprocessing Services Agreement, dated September 22, 2016	
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	Master Services Agreement	
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	Change Order 5 re: MCB and WCB Bioassay Characterization	
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	Change Order 6 re: Establishment of Degraded SEC and Degraded Issi-Asp, CEX & RP Purity Assay Controls	
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	Change Order 6 re: Positional Isomer Feasibility	
Lambda	FUJIFILM DIOSYNTH BIOCTECHOLOGIES USA, INC.	Scope of Work 23	
Lambda	INTRINSIK CORP	Statement of Work 9, dated October 12, 2022, as governed by Master Services	\$0.00

³ The Fujifilm Diosynth Biotechnologies USA, Inc. (“Fuji”) contract cure amounts are subject to resolution among the Debtors, Fuji, and the Purchaser.

Asset	Counterparty	Description of Contract	Cure Amounts
		Agreement, dated March 6, 2020	
Lambda	INTRINSIK CORP	SOW #3, dated February 9, 2022;	
Lambda	INTRINSIK CORP	SOW #5, dated February 23, 2022; and	
Lambda	INTRINSIK CORP	SOW #6, dated March 26, 2022.	
Lambda	Intrinsik Health Sciences Inc.	Proposal Re: Canadian Regulatory Services for Phase II Study for PEG-Interferon Lambda, dated March 4, 2016	
Lambda	KRYOCAL, LLC DBA KYROSPHERE	Statement of Understanding	\$13,125.00
Lambda	Patheon UK Limited	Change of Scope COS-17-R0 to P-MNC- 101564-R3_20220324	\$0.00
Lambda	Patheon UK Limited	Change of Scope COS-P-MNC-101564-R3- COS-08-R3_20210309	
Lambda	Patheon UK Limited	Validation Master Plan	\$0.00
Lambda	Patheon UK Limited; Fisher Clinical Services	Change of Scope Patheon UK_COS 20 P-MNC-101564-R4_20220722	
Lambda	Patheon UK Limited; Fisher Clinical Services	Change of Scope Patheon UK_COS 24 P-MNC-101564-R4_20230209	
Lambda	Patheon UK Limited; Fisher Clinical Services	Change of Scope Patheon UK_COS 29-R0 to P-MNC-101564-R4_20240213	
Lambda	Patheon UK Limited; Fisher Clinical Services	Change of Scope: Prefilled Syringes Patheon UK_P-MNC-101564-R4-COS-23-R0_20220922	
Lambda	RRD INTERNATIONAL, LLC	First Amendment to Project Agreement 3, dated October 1, 2019	\$0.00
Lambda	RRD INTERNATIONAL, LLC	Project Agreement 3 to the Product Development Agreement, dated April 1, 2019, as governed by Product Development Agreement, dated July 1, 2018	

Asset	Counterparty	Description of Contract	Cure Amounts
Lambda	Thermo Fisher Scientific; Patheon UK Limited, Part of Thermo Fisher Scientific	Quotation #220328-01-SF	\$0.00
Lambda	Total Transport Management	Netherlands Hub Freight Quote, dated March 15, 2022	\$0.00
Lambda	Trialog Clinical Trials Ltd	Study Protocol No.: SCRC20006 Agreement, dated April 14, 2020	\$3,760.00
Lambda	Trialog Clinical Trials Ltd	Price Quotation for EIG-LMD-002, dated March 3, 2022	
Lambda	Trialog Clinical Trials Ltd	Price Quotation for EIG-LMD-002, dated July 20, 2022	
Lambda	Trialog Clinical Trials Ltd	Price Quotation for EIG-LMD-002, dated December 7, 2022	
Lambda	Trialog Clinical Trials Ltd	Price Quotation for EIG-LMD-002, dated February 21, 2023	